Home Cell Therapy Creative Biolabs Announced Bio-distribution Analysis Services for CAR-T Cell Therapy

Creative Biolabs Announced Bio-distribution Analysis Services for CAR-T Cell Therapy


Creative Biolabs, a frontier biotech service provider that offers high-quality antibody products, announced today their preclinical viability and bio-distribution analysis services for CAR-T cell therapy.

“All the time, we commit ourselves to promoting the development of CAR-T cell immunotherapy. We all know that CAR-T cell immunotherapy has received huge success for treating hematological malignancies. However, we can’t deny that there still remains a major obstacle related to CAR-T cells therapy. The limited replicative lifespan of CAR-T cells potentially prohibits the long-term therapeutic efficacy of CAR-T cells. And that’s the worth of our CAR-T Bio-distribution study to overcome this difficulty.” a scientist from Creative Biolabs said that.

In addition, despite the great efficacy in some solid tumors in early phase clinical trials, CAR-T cells may bring about some potential toxicities such as cytokine release syndrome, tumor lysis syndrome, neurologic toxicity, on-target/off-tumor recognition, and anaphylaxis.

“Besides our brand new viability and bio-distribution study of CAR-T, we also provide CAR-T toxicity evaluation service. We generally utilize appropriate models, design comprehensive research practices and handle high-quality in vivo studies. We promise that all of the studies are conducted in a GLP-compliant and IACUC-regulated facility. ”

With the tremendously increased demand for modern novel medicine, the CAR and TCR immune cell therapy has been one of the most promising approaches to target-specific cancer treatment. With integrated global resources in all aspects, experienced experts in Creative Biolabs will help you design the program that best meets your purpose and expedite your CAR-T cell therapy to clinical trials.

About Creative Biolabs

As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.

Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: marketing@creative-biolabs.com
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: http://www.creativebiolabs.net

Previous articleEutilex and Huahai Enter Immuno-Oncology Strategic Partnership Paving New Momentum into T Cell Therapy Programs
Next articleCancer immune therapy developed from ‘miraculous’ recovery patients
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.